Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review
References
Additional references
Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of interim FDG‐PET in Hodgkin lymphoma: systematic review and meta‐analysis. British Journal of Haematology 2015;170:356‐66.
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Medicine 2012;9(5):e1001216. [PUBMED: 22675273]
Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. Journal of Clinical Oncology 2014;32:3048‐58.
Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD007941.pub2]
Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging 2010;37(1):181‐200. [PUBMED: 19915839]
Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated‐dose BEACOPP compared with four cycles of escalated‐dose BEACOPP followed by four cycles of baseline‐dose BEACOPP with or without radiotherapy in patients with advanced‐stage Hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Journal of Clinical Oncology 2011;29(32):4234‐42. [PUBMED: 21990399]
Bouwmeester W, Zuithoff NP, Mallett S, Geerlings MI, Vergouwe Y, Steyerberg EW, et al. Reporting and methods in clinical prediction research: a systematic review. PLoS Medicine 2012;9:1‐12.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine 1992;327(21):1478‐84. [PUBMED: 1383821]
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification. Journal of Clinical Oncology 2014;32(27):3059‐68. [PUBMED: 25113753]
Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, et al. Involved‐field radiotherapy is equally effective and less toxic compared with extended‐field radiotherapy after four cycles of chemotherapy in patients with early‐stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 2003;21(19):3601‐8.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended‐field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Journal of Clinical Oncology 2007;25(23):3495‐502.
Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early‐stage Hodgkin's lymphoma. New England Journal of Medicine 2010;363(7):640‐52. [PUBMED: 20818855]
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced‐intensity chemotherapy and PET‐guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open‐label, phase 3 non‐inferiority trial. Lancet 2012;379(9828):1791‐9. [PUBMED: 22480758]
Follows GA, Ardeshna KM, Barrington SF, Culligan DJ, Hoskin PJ, Linch D, et al. Guidelines for the first line management of classical Hodgkin lymphoma. British Journal of Haematology 2014;166(1):34‐49.
Franklin JG, Paus MD, Pluetschow A, Specht L. Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI: 10.1002/14651858.CD003187.pub2; PUBMED: 16235316]
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2‐[18F]fluoro‐2‐deoxy‐D‐glucose positron emission tomography is prognostically superior to international prognostic score in advanced‐stage Hodgkin's lymphoma: a report from a joint Italian‐Danish study. Journal of Clinical Oncology 2007;25(24):3746‐52. [PUBMED: 17646666]
Geersing GJ, Bouwmeester W, Zuithoff P, Spijker R, Leeflang M, Moons KG. Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews. PLoS One 2012;7:e32844.
Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Annals of Internal Medicine 2013;158(4):280‐6. [PUBMED: 23420236]
Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. SEER Cancer Statistics Review, 1975‐2010. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/ based on November 2012 SEER data submission, posted to the SEER web site, April 2013 (accessed 23 June 2015).
Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Systematic reviews 2013;2:71. [PUBMED: 24007720]
Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology 2007;25:571‐8.
Klimm B, Engert A, Diehl V. First‐line treatment of Hodgkin's lymphoma. Current Hematology Reports 2005;4(1):15‐22.
Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first‐line chemotherapy in advanced‐stage Hodgkin lymphoma. Blood 2008;112(10):3989‐94. [PUBMED: 18757777]
Kobe C, Dietlein M, Fuchs M. Interpretation and validation of interim positron emission tomography in Hodgkin lymphoma. Leukemia & Lymphoma2010; Vol. 51, issue 3:552‐3. [PUBMED: 20141443]
Kobe C, Dietlein M, Kriz J, Furth C, Fuchs M, Borchmann P, et al. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. Expert Review of Anticancer Therapy 2010;10(9):1419‐28. [PUBMED: 20836677]
Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. Journal of the National Cancer Institute 2005;97(14):1043‐55. [PUBMED: 16030302]
Kyzas PA, Denaxa‐Kyza D, Ioannidis JP. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. Journal of the National Cancer Institute 2007;99(3):236‐43. [PUBMED: 17284718]
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology 1989;7(11):1630‐6.
Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Chapter 10 Analysing and Presenting Results. In: Deeks JJ, Bossuyt PM, Gatsonis C editor(s). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 1.0. The Cochrane Collaboration, 2010. Available from: http://srdta.cochrane.org/.
Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. British Journal of Cancer 2010;102(1):173‐80. [PUBMED: 19997101]
Markova J, Kobe C, Skopalova M, Klaskova K, Dedeckova K, Plutschow A, et al. FDG‐PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced‐stage Hodgkin's lymphoma has a high negative predictive value. Annals of Oncology 2009;20(7):1270‐4. [PUBMED: 19228806]
Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & Lymphoma 2012;53(1):64‐70. [PUBMED: 21740300]
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). British Journal of Cancer 2005;93:387‐91.
Miltenyi Z, Barna S, Garai I, Simon Z, Jona A, Magyari F, et al. Prognostic value of interim and restaging PET/CT in Hodgkin lymphoma. Results of the CHEAP (Chemotherapy Effectiveness Assessment by PET/CT) study ‐ long term observation. Neoplasma 2015;62:627‐34.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006‐12.
Moons KG, de Groot JA, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Medicine 2014;11:e1001744.
Peat G, Riley RD, Croft P, Morley KI, Kyzas PA, Moons KG, et al. Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. PLoS Medicine 2014;11:e1001671.
Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD009411.pub2; PUBMED: 23784872]
Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N. Hodgkin's lymphoma in adults: diagnosis, treatment and follow‐up. Deutsches Arzteblatt International 2013;110(11):177‐83, 183e1‐3. [PUBMED: 23555321]
Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005;105(12):4553‐60. [PUBMED: 15728122]
Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Rigacci L, Puccini B, Zinzani P L, Biggi A, Castagnoli A, Merli F, et al. The prognostic value of positron emission tomography performed after two courses (INTERIM‐PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). American Journal of Hematology 2015;90:499‐503.
Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA, et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Medicine 2013;10(2):e1001380. [PUBMED: 23393429]
Sauerbrei W. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. Advances in Oto‐Rhino‐Laryngology 2005;62:184‐200. [PUBMED: 15608428]
Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N. Positron emission tomography‐adapted therapy for first‐line treatment in individuals with Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD010533.pub2]
Simon Z, Barna S, Miltenyi Z, Husi K, Magyari F, Jona A, et al. Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma. International Journal of Hematology 2015;103(1):63‐9.
Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, et al. Interim PET after two ABVD cycles in early‐stage Hodgkin lymphoma: Outcomes following the continuation of chemotherapy plus radiotherapy. International Journal of Radiation Oncology Biology Physics 2015;92:1077‐83.
Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, et al. Effect of initial treatment strategy on survival of patients with advanced‐stage Hodgkin's lymphoma: a systematic review and network meta‐analysis. Lancet. Oncology 2013;14(10):943‐52. [PUBMED: 23948348]
Specht L. FDG‐PET scan and treatment planning for early stage Hodgkin lymphoma. Radiotherapy and Oncology2007; Vol. 85, issue 2:176‐7. [PUBMED: 17920143]
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Fourth. Vol. 2, Lyon: WHO Press, 1211 Geneva 27, Switzerland, 2008. [ISBN‐13: 9789283224310]
Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Annals of Oncology 2002;13 Suppl 4:147‐52. [PUBMED: 12401681]
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16.
von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin study group HD14 trial. Journal of Clinical Oncology 2012;30(9):907‐13. [PUBMED: 22271480]
Weiler‐Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F‐FDG avidity in lymphoma readdressed: a study of 766 patients. Journal of Nuclear Medicine 2010;51(1):25‐30.
